Benign prostatic hypertrophy: Review of the efficacy, tolerance and quality of life impact of the long-term treatment with alfuzosin;Hipertrofia benigna de prostata: Revision de la eficacia, tolerancia e impacto en la calidad de vida del tratamiento prolongado con alfuzosina

Actas Urologicas Espanolas

Volumn 24, Issue 2, 2000, Pages 120-130

  Vela Navarrete, R ^a   Gabriel, R ^b   Barajas, R ^c   Ausin, I ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Pharma Consult Services SA   (Spain)

Author keywords

Alfuzosin; Benign prostatic hypertrophy; I PSS questionnaire; Observational study

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; HUMAN; MALE; MULTICENTER STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROSPECTIVE STUDY; TIME; BRADYCARDIA; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERANCE; HEART RATE; HYPOTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; SEXUAL FUNCTION; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUINAZOLINES; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0034136786     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(00)72418-1     Document Type: Article

References (20)

1. J.D. Mcdonell M.M. Barry R.C. Bruskewitz Benign prostatic hyperplasia: diagnosis and treatment clinical practica guideline. Rockville, md: agency for health care policy and research, public health service, us dept o f health and human services february 1994 Ahcpr Publication 94-0582; nº8
2. J.E. Oesterling Benign prostatic hyperplasia Drug Therapy 332 2 1995 99 109
3. M. Caine The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy J Urol 136 1986 1 4
4. I. Cavero P.E. Hicks F. Lefevre-Borg Alpha1- adrenoreceptor antagonist effects of alfuzosin in rabbit and dog lower urinary tract Br J Pharmacol 86 1985 416
5. J.W. Iacovou M. Dunn Indoramin An effective new drug in the managment of bladder out-flow obstruction Br J Urol 60 1987 526 528
6. R.S. Kirby S.W.G. Coppinger M.O. Corcoran Prazosin in the treatment of prostatic obstruction. a placebo-controlled study Br J Urol 60 1987 136 142
7. P.G. Fabricious P. Weizert U. Duzendorfer Efficacy of once-a-day terazosin in benign prostatic hypertrophy: a randomized double-blind placebo- controlled clinical trial Prostate Suppl. 3 1990 85 93
8. K. Kawabe A. Ueno Takimoto Use of an alpha1-blocker. Ym617, in the treatment of benign prostatic hypertrophy J Urol 144 1990 908 912
9. W. Chow D. Hahn D. Sandhu Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy Br J Urol 1990
10. R. Vela Navarrete J.M. Martin F.J. Calahorra J. Damian A. Hernandez P. Boyle Validación cultural y lingüística, en castellano del baremo internacional de sintomatología prostática (I-PSS Actas Urol Esp 18 8 1994 841 847
11. M.J. Barry F.J. Fowler M.P. O’leary R.C. Bruskewitz H.L. Holtgrewe W.K. Mebust A.T.K. Cockett The american urological association symptom index for benign prostatic hyperplasia. The measurement committee of the american urological association J Uro 148 1993 1.549 1.557
12. M.J. Barry J.R. Fowler O’learly R.C. Bruskewitz H.L. Holtgrewe W.K. Mebust Correlation of the american urological association index with selfadministered versions of the madsen-iversen, boyarski and maine medical assesment program symptom indexes. Measurement committee of the american urological association J Uro 148 1992 1.563 1.588
13. R. Vela Navarrete G. Sánchez R. Sobrino M. Tafalla prostatismo en España, perfil clínico del paciente solicitando tratamiento al urólogo Actas Urol Esp 22 Suppl 1998 44 5
14. H. Lepor W.O. Williford M.J. Barry The eficacy of terazosin, finasteride, or both in benign prostatic hyperplasia N England J Med 335 1996 533 539
15. Mc connell jd and the pless study group: The long-term effects of finasteride on bph: results of a four-year, placebo-controlled study Br J Urol 80 Suppl 2 1997 182
16. B. Lukacs D. Comet D. Doublet B. Gattegno P. Thibault Two-year assessment of long-term health-related quality of life (HRQL) of 4591 patients suffering from benign prostatic hypertrophy (BPH) treated with a uroselective alph?-1 blocker, alfuzosin J Urol 155 1996 574 A
17. I. Castillon N. Fernández Hernando V. Alfaro L.L. Badiella R. Vela Navarrete Relación entre edad y baremo sintomático (IPSS) en una población representativa de 2.875 individuos con el diagnóstico clínico de HBP Actas Urol Esp 22 Suppl 1998 44 5
18. A. Jardin H. Bensadoun M.C. Delauche-Cavallier A. Stalla-Bourdillon P. Attali and The Bphalf Group: Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey Br J Urol 74 1994 579 584
19. R.S. Kirby Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia Eur Urol 33 Suppl 2 1998 19 27
20. C.C. Schulman W. De Sy M. Vanderbris M. Tomas J.P. Santoni Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The alfuzosin belgian group Acta Urol Belg 62 4 1994 15 21